Patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) harboring BIM deletion polymorphism (BIM deletion) have poor responses to EGFR TKI. Mechanistically, the BIM deletion induces preferential splicing of the non-functional exon 3-containing isoform over the functional exon 4-containing isoform, impairing TKI-induced, BIM-dependent apoptosis. Histone deacetylase inhibitor, vorinostat, resensitizes BIM deletion-containing NSCLC cells to EGFR-TKI.
| INTRODUC TI ON
The majority of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations, such as exon 19 deletion and an L858R point mutation, show marked responses to EGFR-TKI, such as gefitinib, erlotinib, afatinib, and osimertinib. [1] [2] [3] [4] [5] However, 20%-30% of patients with EGFR-activating mutations show intrinsic resistance to EGFR-TKI. Molecular mechanisms of the intrinsic resistance, including a pre-existing EGFR-T790M resistance mutation-positive clone and the activation of alternative pathways, such as hepatocyte growth factor (HGF)/MET, have been discovered. 6 Decreased activity of BIM, also known as Bcl-2-like protein 11, a proapoptotic molecule that belongs to the Bcl-2 family, has been recognized as an important mechanism mediating intrinsic resistance to EGFR-TKI. BIM upregulation is essential for the induction of apoptosis in lung cancer cells with EGFR mutations treated with first-generation EGFR-TKI, and low BIM protein levels are associated with resistance to EGFR-TKI. 7, 8 Underlying the importance of BIM in EGFR-TKI resistance, a functional BIM deletion polymorphism, specifically, a 2903-bp deletion in intron 2, was discovered in East Asian individuals (13%-18%) and found to confer inferior responses to EGFR-TKI. 9, 10 Subsequently, the BIM deletion was also found in South American patients with NSCLC (15.7%). 11 Mechanistically, the BIM deletion results in the mutually exclusive splicing of exon 3 over the BH3-encoding (proapoptotic) exon 4 in BIM pre-mRNA and leads to the production of an inactive BIM protein isoform (BIMγ) lacking the BH3 domain.
In turn, this reduces the expression of the proapoptotic BIM protein isoform (BIM EL ) in EGFR-mutant lung cancer cell lines following TKI exposure and is sufficient to confer TKI resistance. 9 Several meta-analyses have reported an association between the BIM deletion polymorphism and shorter progression-free survival (PFS) in patients with NSCLC harboring EGFR mutations who received either gefitinib or erlotinib treatment. [12] [13] [14] [15] [16] [17] Therefore, restoration of BIM activity in patients with the BIM deletion may be an important strategy to overcome intrinsic resistance to EGFR-TKI in EGFR-mutated NSCLC.
Vorinostat (suberoylanilide hydroxamic acid [SAHA]), has been approved in 20 countries to date, including Japan, for cutaneous T-cell lymphoma as monotherapy. It is a small-molecule inhibitor of histone deacetylase (HDAC) that causes the acetylation of histone proteins, including histone H2, and induces cell differentiation, cell cycle arrest, and apoptosis in several types of tumor cells. 18 We previously reported that the combined use of vorinostat and gefitinib was able to preferentially induce transcription of the proapoptotic exon 4-containing BIM isoform over the inactive exon 3-containing isoform, thus resensitizing BIM deletion-containing EGFR-mutated NSCLC cell lines to TKI in vitro and in vivo. 19 Two clinical trials combining TKI and vorinostat have been conducted: a phase I/II study in patients with advanced NSCLC, regardless of the presence/absence of EGFR mutation in Korea, 20 and a phase I/II study in patients with advanced EGFR-mutated NSCLC after EGFR-TKI progression in Spain. 21 However, neither combination regimen showed significant efficacy in these populations, suggesting the need for improved patient selection and the development of pharmacodynamic biomarkers of vorinostat activity.
Based on our preclinical findings, we designed the present phase I study, named VICTORY-J "Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphism in EGFR Mutant Lung Cancer", to evaluate the safety of combined therapy with vorinostat and gefitinib, and to determine the maximum tolerated dose EGFR-mutated NSCLC with the BIM deletion, pretreated with EGFR-TKI and chemotherapy, were recruited. Vorinostat (200, 300, 400 mg) was given daily on days 1-7, and gefitinib 250 mg was given daily on days 1-14. Vorinostat doses were escalated based on a conventional 3 + 3 design. Pharmacodynamic markers were measured using PBMC collected at baseline and 4 hours after vorinostat dose on day 2 in cycle 1. No dose-limiting toxicities (DLT) were observed in 12 patients. We determined 400 mg vorinostat as the recommended phase II dose (RP2D). Median progressionfree survival was 5.2 months (95% CI: 1.4-15.7). Disease control rate at 6 weeks was 83.3% (10/12). Vorinostat preferentially induced BIM mRNA-containing exon 4 over mRNA-containing exon 3, acetylated histone H3 protein, and proapoptotic BIM EL protein in 11/11, 10/11, and 5/11 patients, respectively. These data indicate that RP2D was 400 mg vorinostat combined with gefitinib in BIM deletion/EGFR mutation double-positive NSCLC. BIM mRNA exon 3/exon 4 ratio in PBMC may be a useful pharmacodynamic marker for treatment.
K E Y W O R D S
BIM deletion polymorphism, EGFR-TKI, NSCLC, resistance, vorinostat (MTD) and recommended phase II dose (RP2D) of vorinostat combined with a fixed dose of gefitinib for patients with EGFR-mutated NSCLC harboring the BIM deletion polymorphism. 22 In addition, we conducted pharmacodynamic analyses to identify biomarkers of vorinostat activity. ClinicalTrials.gov (NCT02151721).
| MATERIAL S AND ME THODS

| Study design
| Patient eligibility
Prior to enrolment in the study, patients had to fulfil all of the following criteria: histologically or cytologically diagnosed NSCLC (excluding squamous cell carcinoma); NSCLC of clinicopathological stage IIIB or IV for which radical radiation therapy was impractical or there was a recurrence after surgery; EGFR mutations (deletion of exon 19 and L858R mutation of exon 21) for which the clinical benefits of an EGFR-TKI (gefitinib, erlotinib, or afatinib) were recognized by testing methods that were listed by the national health insurance; history of treatment with an EGFR-TKI (gefitinib, erlotinib, or afatinib) and a history of pathological deterioration during treatment; history of treatment with cytotoxic anticancer agents (not including pre-or postoperative chemotherapy in the previous 1 year or more from the day of final dose); confirmed BIM polymorphism by the PCR fragment analytical method and the sequence method at the central laboratory; a lesion measurable according to the RECIST guidelines version 1.1; 20 years of age and older; ECOG Performance Status (PS) 0 or 1; estimated life expectancy of 12 or more weeks; provision of written informed consent to participate in the present study; and adequate hematological, liver, renal, and respiratory function within 14 days before entry.
Patients were excluded for any of the following reasons: received a cytotoxic anticancer agent within the past 4 weeks, received an EGFR-TKI within the past 7 days, or surgery or radiotherapy for a primary tumor or mediastinum within the past 6 months; interstitial lung disease or history thereof, radiation pneumonitis treated with corticosteroids or a history thereof; detection of known resistance mutations of EGFR (eg, T790M).
Between March 2014 and February 2017, 527 patients with advanced EGFR-mutated NSCLC were screened for BIM deletion polymorphism. Among them, 77 patients (14.6%) had BIM deletion polymorphism (75 patients [14. 2%] were heterozygous and two patients [0.4%] were homozygous) and a total of 12 patients were enrolled in the present study.
| Treatment and assessment
Vorinostat and gefitinib were purchased from Taiho Pharmaceutical and AstraZeneca, respectively. Vorinostat (level 1: 200 mg, level 2: 300 mg, level 3: 400 mg) was given orally once daily on days 1-7, and 250 mg gefitinib was given orally once daily in a cycle of 14 days; this continued until the criteria for respite, dosage reduction, or discontinuation of the protocol treatment were met.
Toxicities were graded in accordance with the NCI Common We assessed the objective tumor response in accordance with version 1.1 of the revised RECIST guidelines. 23 At baseline, we carried out imaging of the chest and abdominal by computed tomography (CT) and brain magnetic resonance imaging (MRI) or CT within 28 days before randomization. After the start of treatment, assessments were carried out at 6-week intervals during the first 24 weeks and at 12-week intervals after this period. Brain MRI or CT was required to follow the same schedule, but only for patients with brain metastasis at the time of enrolment (Table S1 ). Investigators reviewed the images of patients.
PFS was defined as the time from the start of protocol treatment to the first occurrence of progression or to death. OS was defined as the time from the start of protocol treatment to death. DCR was defined as the proportion of patients who achieved complete response, partial response, and stable disease for at least 6 weeks.
| Statistical analysis
The population analyzed for the primary endpoint included the enrolled patients with complete safety data on DLT during the first two cycles.
| Genotyping of the BIM deletion polymorphism
Cellular DNAs were extracted from patients' PBMC using a DNeasy Blood and Tissue Kit (Qiagen). To recognize the presence of the wild-type and deletion alleles, we conducted PCR as reported previously. 19 Primer sequences used were as follows. Forward: 5′-CCACCAATGGAAAAGGTTCA-3, reverse: Proteins harvested from PBMC were separated by SDS-PAGE.
| Pharmacokinetic analysis
The proteins were transferred onto PVDF membranes (Bio-Rad); the membranes were immersed in StartingBlock T20 (TBS) Blocking Buffer (ThermoFisher Scientific) for 1 hour at approximately 20°C, and by incubation for longer than 8 hours at 4°C with antibodies against acetylated histone H3 (Lys27), BIM, and β-actin (Cell Signaling Technology). After three washes in Tris-buffered saline with polyoxyethylene sorbitan monolaurate (TBST), the membranes were incubated for 1 hour at room temperature with HRP-conjugated secondary antibodies. Proteins labeled with secondary antibodies were visualized by using SuperSignal West Dura Extended Duration Substrate Enhanced Chemiluminescent Substrate (ThermoFisher Scientific).
| RE SULTS
| Patients and safety
From June 2014 to February 2017, 12 patients were enrolled into this study. Patient characteristics are summarized in Table 1 . Previously treated EGFR-TKI in each patient are shown in Table S2 .
Planned dose escalation was completed without reaching the MTD. DLT were not observed in any patients. Treatment-related adverse events are summarized in Table 2 . The most common adverse events were diarrhea (92%), anorexia (75%), oral mucositis (58%), rash, weight loss, dysgeusia, nausea (50%), vomiting, and malaise (42%).
Treatment-related grade 3 adverse events included grade 3 hypokalemia (17%), lung infection and thrombocytopenia (8%) ( Table 3) . No treatment-related death or grade 4 adverse events were observed.
Adverse events that resulted in drug cessation were observed in four cases: one at level 1 (pneumonia); two at level 2 (diarrhea, vomiting, fever, alanine aminotransferase [ALT] elevation, and loss of appetite); and one at level 3 (neutropenia). One adverse event resulting in vorinostat dose reduction was observed at level 2 (thrombocytopenia).
Based on these data, RP2D was determined as 250 mg gefitinib daily and 400 mg/day vorinostat biweekly.
| Efficacy
Median PFS and OS of 12 patients at levels 1-3 were 156.5 days (5.2 months; 43-479 days) and 673 days (22.4 months; 411 days-not reached), respectively (Figure 1 ). Disease control (stable disease assessed for at least 6 weeks) was achieved in 10 out of 12 (83.3%) patients with a history of progressive disease during EGFR-TKI treatment ( Table 4 ).
| Pharmacokinetics
Median T max of vorinostat in the 200, 300, and 400 mg groups was 2, 4, and 4 hours, respectively (Table 5, Figure S2 ); T 1/2 (mean ± SD) was 3.6 ± 3.4, 1.5 ± 0.5, and 2.0 ± 1.1 hours, respectively, and C max (mean ± SD) was 602 ± 166, 661 ± 33, and 1010 ± 335 nmol/L, respectively. AUC last (mean ± SD) was 2340 ± 753, 2430 ± 348, and 4790 ± 2040 nmol·h/L, respectively, and AUC inf (mean ± SD) was 2430 ± 809, 2480 ± 407, and 4810 ± 2040 nmol·h/L, respectively.
Median T max of gefitinib in the 200, 300, and 400 mg groups was 4, 4, and 4.1 hours, respectively ( Figure S3 ); T 1/2 (mean ± SD) was 20.2 ± 7.3, 25.1 ± 5.5, and 25.2 ± 11.4 hours, respectively, and C max (mean ± SD) was 344 ± 44, 240 ± 98, and 295 ± 253 ng/mL, respectively. AUC last (mean ± SD) was 4524 ± 779, 3398 ± 1050, and 3853 ± 3004 ng·h/L, respectively, and AUC inf (mean ± SD) was 8674 ± 3064, 7333 ± 1808, and 9537 ± 8064 ng·h/L, respectively.
There was no significant difference between the three groups. 
TA B L E 1 Characteristics of patients with EGFR-mutated NSCLC harboring BIM deletion polymorphism
TA B L E 2 Number of patients with treatment-related adverse events
These results indicated that vorinostat was unlikely to affect the pharmacokinetics of gefitinib.
| Pharmacodynamics
Pharmacodynamic analyses of PBMC obtained at baseline and 4 hours after giving vorinostat and gefitinib on day 2 in cycle 1
were carried out. As a measure of the effects of vorinostat on the expression and splicing of BIM transcripts, we evaluated, by using real-time qPCR, BIM exon 2 expression as a surrogate expression marker for all BIM transcripts. In addition, we also separately evaluated the expression of BIM exon 3 and exon 4, which represent the BIM isoform that lacks the proapoptotic BH3 domain and the isoform that has the proapoptotic BH3 domain, respectively.
In two cases, (VK-02) and (VS-02), we were unable to measure these parameters owing to poor quality of the mRNA and protein, respectively.
We found that the BIM mRNA exon 3/exon 4 ratio was decreased by treatment with gefitinib and vorinostat in all 11 patients assessed (Figure 2A,B) . As reported, HDAC inhibitors, alone or in combination with a TKI, may cause the expression of proapoptotic exon 4-containing BIM transcripts to increase by significantly more than the expression of exon 3-containing BIM transcripts. 19, 26, 27 We also noted that VI-03, the only patient in this study that was homozygous for the BIM deletion polymorphism, had the highest expression of exon 3-containing transcripts, as well as the highest exon 3/exon 4 ratio at baseline. This was in line with our previous findings that cells that were homozygous for the BIM deletion polymorphism tended to have higher expression of exon 3-containing transcripts than of the proapoptotic exon 4-containing transcripts. 9, 26 Mean odds ratio of exon 3/exon 4 before and after treatment with gefitinib and vorinostat was 1.9376 (1.5988 at level 1, 1.8436 at level 2, and 2.1974 at level 3), and the results showed a significant upward trend in terms of a vorinostat dose-dependent increase in proapoptotic exon 4-containing BIM transcripts ( Figure 2C ).
In addition, we also assessed the acetylation status of histone H3
as a measure of the inhibitory effect of vorinostat on HDAC activity. 28 We also evaluated the protein expression of the pro-apoptotic Median OS: 22.1 mo (95% CI: 13.5, -)
combination with a TKI, which can increase the protein expression of BIM. 19, 26, 27 Therefore, these data have shown the technical feasibility of monitoring these parameters as markers of vorinostat activity.
| D ISCUSS I ON
In the present study, we determined the RP2D of vorinostat, was evaluated in erlotinib-refractory EGFR-mutated NSCLC. 21 In the Korean phase I/II trial, vorinostat plus gefitinib (250 mg daily) was evaluated in unselected NSCLC. 20 Both trials determined the recommended dose of vorinostat as 400 mg/day biweekly, but drug concentrations in the plasma or serum were not evaluated.
Therefore, the pharmacokinetic interactions of vorinostat and EGFR-TKI have been unknown until now. In our study, we showed that selection of patients with both an EGFR mutation and the BIM deletion polymorphism could be carried out in a clinical setting, and that vorinostat 400 mg/day biweekly was the recommended dose for further studies in BIM deletion polymorphism/EGFR mutationpositive populations in NSCLC. Furthermore, our pharmacokinetic analyses showed that vorinostat did not affect the dynamics of gefitinib in these populations.
The most important and informative findings in our study are the pharmacodynamic analyses. We found that vorinostat, in combination with gefitinib, induced acetylated histone H3 protein expres- It is well recognized that a small population of cells adapts to initial treatment with EGFR-TKI as persisters and becomes the base of acquired resistant lesions. 29 after the induction of gefitinib resistance in the in vitro condition. 26 Although we did not examine additional resistance mechanisms in specimens from patients enrolled in the VICTROY-J study, resistant factors other than EGFR-T790M might also be detectable.
Prognosis of patients with T790M-negative, EGFR-mutated NSCLC who are refractory to EGFR-TKI is reported to be very poor. [30] [31] [32] [33] In the present study, we excluded patients with EGFR-T790M-positive NSCLC because our previous in vitro results showed that vorinostat did not sensitize T790M-positive EGFRmutated NSCLC cells to gefitinib. 19 Therefore, we recruited patients with T790M-negative EGFR-mutated NSCLC who were refractory to EGFR-TKI, and who had been treated with at least one regimen of cytotoxic chemotherapy. As a result, our study comprised heavily pretreated patients. Although the limited number of patients in our study precludes firm conclusions about clinical benefit, the DCR of 83.3% and median PFS of 5.2 months suggests that the combination should be evaluated in phase II studies.
In addition to the gefitinib/vorinostat combination we evaluated, the concept of combining EGFR-TKI and HDAC inhibitors can be applied by using new-generation EGFR-TKI, as well as novel HDAC inhibitors that have recently been described. Recently, the third-generation EGFR-TKI, osimertinib, has been recognized as one of the standard drugs for first-line treatment of EGFR-mutated NSCLC. 5
However, a population of patients show intrinsic resistance, even to osimertinib. 5 In these patients, resistance may be mediated by the BIM deletion polymorphism, as we found that BIM deletion polymorphism-positive EGFR-mutated NSCLC cell lines (PC-3) were resistant to osimertinib-induced apoptosis 19, 26 ; importantly, the addition of vorinostat could resensitize these cells to EGFR-TKI. Moreover, we reported that HDAC3 was an important regulator of BIM pre-mRNA splicing and that the activity of vorinostat was likely to require inhibition of HDAC3. 26 Therefore, the combination of osimertinib and new-generation HDAC inhibitors, including HDAC3-selective inhibitors and others (eg, panobinostat), 34 might be a promising first-line treatment for BIM deletion polymorphism-positive EGFR-mutated NSCLC.
In conclusion, we have determined vorinostat at 400 mg/day biweekly combined with gefitinib 250 mg daily as the recommended dose for phase II studies in patients with NSCLC who are double-positive for BIM deletion polymorphisms and EGFR mutations. Further, it is warranted to evaluate our approach for exploration of the efficacy of combination EGFR-TKI/HDAC therapy in larger cohorts.
